Key Investor Signals
Signed a public-research partnership for NeurAll
Fundación Progreso y Salud signed a March 2025 agreement with ATS covering development and exploitation of gene-therapy research led at CABIMER.
Advanced nanoparticle testing in preclinical models
By June 2026, the research team had evaluated multiple particles for efficacy, compatibility and safety and was testing vectors in proof-of-concept studies.
Established a nearly €500,000 research-project budget
The March 2025 NeurAll agreement described a project budget close to €500,000, combining private and public resources with seed capital contributed by ATS.
Other Positive Signals
- Gained project support from the ENACH and Mácula Retina-Gen CRB1 patient associations.
Team
Antonio López
Founder
- Presides over ENACH, a patient association supporting families affected by rare brain-iron disorders and funding therapeutic research.
- Took the initiative to establish ENACH in 2013 and built a patient-led organization focused on research funding and family support.
- Led ENACH's research partnership with Pablo de Olavide University from 2014, including BPAN and drug-toxicity research lines.
Product
NeurAll is a preclinical platform using non-viral vectors to transport genetic material. Researchers at CABIMER are evaluating nanoparticle candidates for delivery to brain and retinal cells, with PANK2 and CRB1 among the initial genetic targets.
Nanoparticle gene delivery
The platform packages genetic material in nanoparticles instead of viral carriers. The research aims to improve delivery, cargo capacity and flexibility while evaluating the biological compatibility and safety of each candidate.
Brain and retinal targets
Initial work focuses on PANK2-linked neurodegeneration and CRB1-related retinal disease. Both programs seek to address inherited defects, while adapting the genetic cargo and delivery approach to the cells affected.
Preclinical candidate selection
Researchers compare candidate particles in preclinical models and run proof-of-concept tests. Results are intended to identify a lead for regulatory preclinical work before an application to begin a human trial.
Market Overview
Rare neurological and retinal disorders require gene-specific diagnosis and treatment development. Their small patient populations complicate recruitment, while irreversible loss of nerve or retinal cells makes timing important. Delivery platforms must reach the right cells and preserve function without unacceptable toxicity.
Approved retinal gene therapy provides a commercial and regulatory precedent for treating inherited disease, but access and payment remain difficult. Development typically involves specialist centres, genetic testing and long-term follow-up. A new non-viral platform would need disease-specific efficacy, manufacturing and safety evidence.
Suggested worldwide prevalence of PANK2-related neurodegeneration
Estimated frequency of retinitis pigmentosa in the United States and Europe.
CRB1 accounts for about 10% of Leber congenital amaurosis or early-onset severe retinal dystrophy.
US launch list price for treating both eyes with Luxturna in 2018
Comparable Outcomes
Gyroscope Therapeutics
Developed gene therapies for retinal diseases by targeting biological pathways involved in vision loss. Novartis completed the purchase in February 2022 for $800M upfront and up to $700M in contingent milestones.
AveXis
Developed gene replacement therapy that addressed the underlying cause of spinal muscular atrophy. Novartis completed its $8.7B cash acquisition of AveXis in May 2018, adding a gene-replacement program for spinal muscular atrophy.
Interested in More Startups Like Advanced Therapy System?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.